Image for Gradientech presents new QuickMIC® results at NSCMID 2023
IR Press releases 2023-09-21

Gradientech presents new QuickMIC® results at NSCMID 2023

Gradientech will present new promising data from an ongoing study of the QuickMIC® rapid AST system at the the 39th annual NSCMID meeting in Örebro, Sweden, 21-24 September.

Organised by the Nordic Society of Clinical Microbiology and Infectious Diseases, NSCMID aims at strengthening the bonds between clinicians and researchers in clinical microbiology and infectious diseases. The scientific program will include state of the art lectures from international experts, poster exhibition and young scientists’ session.

“We are proud to participate and share new promising QuickMIC data from an ongoing European study with leading experts in the field. QuickMIC is the fastest phenotypic antibiotic susceptibility testing (AST) system for sepsis samples on the market today with results available within 2-4 hours from positive blood culture and fills a significant need in the microbiology laboratory. In combination with its precise, linear MIC results, we believe we are taking AST to a whole new level of clinical utility”, says Sara Thorslund, CEO of Gradientech.

The QuickMIC system will also be showcased at the exhibition at the meeting. This will be done in collaboration with Triolab, Gradientech’s appointed Swedish distributor.

The QuickMIC system and its Gram-negative panel are CE-marked and commercially available in Europe but not yet available for sale in the United States.



For further information, please contact:
Sara Thorslund, PhD, CEO

Tel: +46 736 29 35 80


About Gradientech

Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC®, classified as a breakthrough device by the U.S. Food and Drug Administration, allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala, Sweden. Visit for more information.